Histone Deacetylase Inhibitors in Cancer Therapy
- 1 January 2006
- journal article
- review article
- Published by Taylor & Francis in Cancer Investigation
- Vol. 24 (5), 521-527
- https://doi.org/10.1080/07357900600814979
Abstract
No abstract availableThis publication has 72 references indexed in Scilit:
- Histone deacetylase inhibitors and the promise of epigenetic (and more) treatments for cancerNature Reviews Cancer, 2006
- CLINICAL DEVELOPMENT OF HISTONE DEACETYLASE INHIBITORS AS ANTICANCER AGENTSAnnual Review of Pharmacology and Toxicology, 2005
- Suberoylanilide hydroxamic acid combined with gemcitabine enhances apoptosis in non–small cell lung cancerSurgery, 2005
- Phase I and Pharmacokinetic Study of MS-275, a Histone Deacetylase Inhibitor, in Patients With Advanced and Refractory Solid Tumors or LymphomaJournal of Clinical Oncology, 2005
- Suberoylanilide hydroxamic acid (SAHA) has potent anti‐glioma properties in vitro, ex vivo and in vivoJournal of Neurochemistry, 2005
- Enhancement of Xenograft Tumor Radiosensitivity by the Histone Deacetylase Inhibitor MS-275 and Correlation with Histone HyperacetylationClinical Cancer Research, 2004
- Histone deacetylase inhibitors FK228, N‐(2‐aminophenyl)‐4‐[N‐(pyridin‐3‐yl‐methoxycarbonyl)amino‐ methyl]benzamide and m‐carboxycinnamic acid bis‐hydroxamide augment radiation‐induced cell death in gastrointestinal adenocarcinoma cellsInternational Journal of Cancer, 2004
- Translating the Histone CodeScience, 2001
- Structure of histone acetyltransferases 1 1Edited by P. W. WrightJournal of Molecular Biology, 2001
- Post-translational modification of α-tubulin by acetylation and detyrosination in NB2a/d1 neuroblastoma cellsDevelopmental Brain Research, 1990